Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 15/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210414 | 1.00 | F2R (1.00) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL29413913 | 1.00 | F2R (1.00) | F2RKDM4EMEN1TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL29514998 | 0.99 | F2R (0.98) | F2RKDM4EMEN1TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL17261836 | 0.99 | F2R (0.98) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL15324357 | 0.88 | F2R (0.78) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL24166774 | 0.87 | F2R (0.77) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL24164678 | 0.85 | F2R (0.74) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL24166733 | 0.85 | F2R (0.73) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL4256302 | 0.85 | F2R (0.73) | F2RKDM4EMEN1TP53CYP1A2 | |
| SCHEMBL24165333 | 0.83 | F2R (0.71) | F2RKDM4EMEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140308296-A1 | PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2014-10-16 | — | — | US | claimed |
| US-8802623-B2 | PAR-1 antagonists for use in the treatment or prevention of influenza virus type A infections | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2014-08-12 | — | — | US | claimed |
| EP-2501395-A1 | PAR-1 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS | Institut National De La Recherche Agronomique (FR) | 2012-09-26 | — | — | EP | claimed |
| EP-2335717-A1 | PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2011-06-22 | — | — | EP | claimed |
| WO-2011058183-A1 | PAR-1 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2011-05-19 | — | — | WO | claimed |
| US-12150939-B2 | Therapeutic drug for ectopic ossification having mechanism to inhibit PAR1 | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2024-11-26 | — | — | US | disclosed |
| US-20210161872-A1 | THERAPEUTIC DRUG FOR ECTOPIC OSSIFICATION HAVING MECHANISM TO INHIBIT PAR1 | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2021-06-03 | — | — | US | disclosed |
| US-20200253942-A1 | THERAPEUTIC DRUG FOR ECTOPIC OSSIFICATION HAVING MECHANISM TO INHIBIT PAR1 | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3378490-B1 | ECTOPIC OSSIFICATION TREATMENT DRUG HAVING MECHANISM FOR BLOCKING PAR1 | UNIV KUMAMOTO NAT UNIV CORP (JP) | 2020-07-15 | — | — | EP | disclosed |
| WO-2020008262-A2 | USES FOR CALCIUM CHANNEL MODULATORS | MENRI GROUP LTD (IL) | 2020-01-09 | — | — | WO | disclosed |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | disclosed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | disclosed |
| US-20160045506-A1 | USE OF INHIBITORS OF BINDING BETWEEN A PAR-1 RECEPTOR AND ITS LIGANDS FOR THE TREATMENT OF GLIOMA | UNIVERSITY OF ROCHESTER (US) | 2016-02-18 | — | — | US | disclosed |
| EP-1799243-B1 | TREATMENT OF PULMONARY HYPERTENSION USING AN AGENT THAT INHIBITS A TISSUE FACTOR PATHWAY | UNIV ROCHESTER (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015090705-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2015-06-25 | — | — | WO | disclosed |
| US-20140378502-A1 | Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections | UNIVERSITé LAVAL (CA) | 2014-12-25 | — | — | US | disclosed |
| EP-2709630-A1 | PAR1 INHIBITORS FOR USE IN THE TREATMENT OR PREVENTION OF PARAMYXOVIRIDAE INFECTIONS | Université Laval (CA) | 2014-03-26 | — | — | EP | disclosed |
| US-8563511-B2 | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway | UNIVERSITY OF ROCHESTER (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2012151687-A1 | PAR1 INHIBITORS FOR USE IN THE TREATMENT OR PREVENTION OF PARAMYXOVIRIDAE INFECTIONS | UNIVERSITé LAVAL (CA) | 2012-11-15 | — | — | WO | disclosed |
| EP-2335717-A1 | PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | F2R, F2RL1, SERPINB1 | F2R 1/4885KDM4E 3112/4885MEN1 2825/4885 |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | F2R, F2RL1, SERPINB1 | F2R 1/4885KDM4E 3112/4885MEN1 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.